{"id":"NCT00195676","sponsor":"Abbott","briefTitle":"Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-05","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2005-09-20","resultsPosted":"2010-11-19","lastUpdate":"2011-04-13"},"enrollment":1469,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Adalimumab","type":"OTHER"}],"summary":"The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.","primaryOutcome":{"measure":"Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R","timeFrame":"Week 16 of Period R","effectByArm":[{"arm":"Period R Modified Intent-to-Treat Population","deltaMin":76.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":104,"countries":["United States","Austria","Belgium","Canada","France","Germany","Poland","Puerto Rico","Spain","Switzerland"]},"refs":{"pmids":["21752491","21083543"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":189,"n":1468},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Hypertension","Arthralgia"]}}